Drug Search Results
More Filters [+]

ALLO-213

Alternative Names: ALLO-213, ALLO213, ALLO 213
Latest Update: 2023-01-25
Latest Update Note: News Article

Product Description

Mechanisms of Action: CAR-T,DLL3

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Allogene Therapeutics
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: David Chang
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ALLO-213

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events